FATE THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Class III Directors: Dr. Bahram Valamehr

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Bahram Valamehr, Ph.D., M.B.A.”): 67,859,201 for, 687,732 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 21,921,029 for, 35,418 withheld.

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

Description as filed by funds: Election of Class III Directors: Dr. Shefali Agarwal

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Shefali Agarwal”): 65,856,345 for, 2,690,588 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 21,377,121 for, 579,326 withheld.

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

Description as filed by funds: Election of Class III Directors: Matthew C. Abernethy

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Matthew C. Abernethy, M.B.A.”): 67,935,382 for, 611,551 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 21,921,029 for, 35,418 withheld.

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

Description as filed by funds: TO APPROVE THE AMENDMENT OF OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK FROM 250,000,000 TO 350,000,000.

The 45 asset managers below reported 21,858,924 for, 84,518 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEETING TO APPROVE ANY OF THE ABOVE PROPOSALS.

FATE THERAPEUTICS INC.’s own tally for this item (“(vii) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.”): 72,616,994 for, 15,306,292 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,114,551 for, 2,793,473 against, 35,418 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER.

FATE THERAPEUTICS INC.’s own tally for this item (“(vi) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder.”): 51,379,958 for, 16,912,205 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 46 managers: 17,498,099 for, 4,422,930 against, 35,418 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 2 managers: 412,103 for, 840 against.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

FATE THERAPEUTICS INC.’s own tally for this item (“(iii) Non-binding advisory vote on compensation of the Company's named executive officers.”): 63,041,954 for, 5,198,616 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 45 managers: 20,458,828 for, 1,449,196 against, 35,418 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 114 managers: 31,997,536 for, 2,481,953 against, 1,500 abstained, 39,105 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder advisory votes to approve the compensation of the Company's named executive officers.

FATE THERAPEUTICS INC.’s own tally for this item (“(iv) Non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.”): 77,265,107 for, 10,557,548 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 46 managers: 35,418 abstained, 20,865,507 1 year, 1,055,522 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 112 managers: 457,087 for, 1,058 against, 1,500 abstained, 37,051,792 1 year, 96,747 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.

FATE THERAPEUTICS INC.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 87,110,990 for, 566,323 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 21,920,608 for, 421 against, 35,418 abstained.

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.